1. Volume 3, Issue 3, Pages 196-199 (May 2017)
Complete durable remission of a fulminant primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma after autologous and allogeneic hematopoietic stem cell transplantation 
Kerasia-Maria Plachouri, MD, Carsten Weishaupt, MD, Dieter Metze, MD, Georg Evers, MD, Wolfgang E. Berdel, MD, Werner Kempf, MD, Cord Sunderkötter, MD, Matthias Stelljes, MD 
JAAD Case Reports 
Volume 3, Issue 3, Pages (May 2017)
DOI: /j.jdcr
Copyright © 2017 American Academy of Dermatology, Inc. Terms and Conditions

2. Fig 1
Primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma. Status before therapy with methotrexate.
JAAD Case Reports 2017 3, DOI: ( /j.jdcr )
Copyright © 2017 American Academy of Dermatology, Inc. Terms and Conditions

3. Fig 2
Primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma. Status after therapy with methotrexate and before the CHOEP regimen.
JAAD Case Reports 2017 3, DOI: ( /j.jdcr )
Copyright © 2017 American Academy of Dermatology, Inc. Terms and Conditions

4. Fig 3
Primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma. Status directly after the CHOEP regimen.
JAAD Case Reports 2017 3, DOI: ( /j.jdcr )
Copyright © 2017 American Academy of Dermatology, Inc. Terms and Conditions

5. Fig 4
Primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma. Status directly after allogeneic stem cell transplantation.
JAAD Case Reports 2017 3, DOI: ( /j.jdcr )
Copyright © 2017 American Academy of Dermatology, Inc. Terms and Conditions

6. Fig 5
Primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma. Status after allogeneic stem cell transplantation.
JAAD Case Reports 2017 3, DOI: ( /j.jdcr )
Copyright © 2017 American Academy of Dermatology, Inc. Terms and Conditions